Cargando…

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN

Detalles Bibliográficos
Autores principales:	Munawar, U., Theuersbacher, J., Haertle, L., Zhou, X., Han, S., Regensburger, A., Mersi, J., Bittrich, M., Seifert, F., Haider, M.S., Nerreter, S., Vogt, C., Teufel, E., Einsele, H., Rasche, L., Kampik, D., Kortüm, K.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171742/ http://dx.doi.org/10.1097/01.HS9.0000936304.11663.09

Ejemplares similares

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Rathi, Chetan, et al.
Publicado: (2021)

Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin
por: Springer, Carsten, et al.
Publicado: (2023)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Belantamab mafodotin associated corneal microcyst-like epithelial changes
por: Chuang, Katherine, et al.
Publicado: (2022)

Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences
por: Morè, Sonia, et al.
Publicado: (2023)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
por: Nooka, A., et al.
Publicado: (2023)

P41 NO EVIDENCE OF B-CELL MATURATION ANTIGEN (BCMA) EXPRESSION LOSS OR SYSTEMIC IMMUNE IMPAIRMENT AFTER TREATMENT WITH THE BCMA-TARGETED ANTIBODY-DRUG CONJUGATE BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lowther, D.E., et al.
Publicado: (2023)

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
por: Wahab, Ahsan, et al.
Publicado: (2021)

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

P20: POLYCENTRIC “REAL LIFE” STUDY OF BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Iula, R, et al.
Publicado: (2022)

Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma
por: Popat, Rakesh, et al.
Publicado: (2023)

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2021)

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
por: Neupane, Karun, et al.
Publicado: (2021)

Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
por: Lonial, Sagar, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up
por: Cohen, Adam D, et al.
Publicado: (2020)

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA
por: Zhou, X., et al.
Publicado: (2023)

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
por: Montes de Oca, Rocio, et al.
Publicado: (2021)

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS
por: Khwaja, J., et al.
Publicado: (2022)

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
por: Collins, Jon, et al.
Publicado: (2023)

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
por: Shah, Anshul, et al.
Publicado: (2021)

P890: COMBINING SKY92 GENE EXPRESSION PROFILING WITH CYTOGENETICS ACCORDING TO R2-ISS FOR MULTIPLE MYELOMA RISK CLASSIFICATION: THE FIRST PROSPECTIVE EVIDENCE
por: Zhou, Xiang, et al.
Publicado: (2023)

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
por: Joseph, Nisha S, et al.
Publicado: (2021)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience
por: Iula, Rossella, et al.
Publicado: (2022)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
por: de la Rubia, Javier, et al.
Publicado: (2023)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
por: Iida, Shinsuke, et al.
Publicado: (2023)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
por: Zhou, X., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g6jo7f7l28u4tt3r5a2m64i5qq